EE Impact

Orion Pharma

Finland · Pharma & Healthcare

LeaveRussia detail: Exit Completed

Exited Russia

Orion Corporation (Orion Pharma), founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets.

Status last verified 03/08/2026Source checked 30/09/2025Company website ↗LeaveRussia profile ↗

Decision trail

Decision date 19/07/2025 · Reference ↗

Stop exports to Russia. Finnish Orion Pharma has started the liquidation of its Russian office - it is planned to be closed by the end of 2022. Divested the rights of some of its self-care brands in Russia. Finnish drug manufacturer Orion Pharma is suffering critical losses after leaving the Russian market. The exit itself was not complete because there were no changes in the ownership structure. Also, according to preliminary data, the company's management expects to return to the Russian market in the near future. 19.07.2025: Aleksandr Mayevich Prilepin is no longer the organization's CEO. Anastasia Artemovna Katanisi has become the liquidator of ORION PHARMA.

Local stats (LeaveRussia)

Assets(RF), mln.USD
1
Capital(RF), mln.USD
1
Glob.Revenue, mln.USD
748
Plants
3
Revenue(RF), mln.USD
0
Staff(RF), 2021
449
Taxes(RF), mln.USD
1

Status history since 2022

  1. 03/08/2026 exited · Imported from KSE LeaveRussia

Exposure profile

Full exposure profile is a Professional feature

Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.

Upgrade to Professional
Statuses, logos and narrative notes are compiled from public reporting and the KSE LeaveRussia project. Found an error? See our corrections policy.